ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 39347709

UBA1 dysfunction in VEXAS and cancer.

Sakuma M and 2 others. Oncotarget, 2024. Cited by 15 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. UBA1 dysfunction in VEXAS and cancer. Papers, record 39347709. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39347709

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
UBA1 dysfunction in VEXAS and cancer.
PubMed
Journal
Oncotarget
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
1.97, provisional
iCite
Revised in PubMed
2026-04-28
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sakuma MMaki
2Haferlach TTorsten
3Walter WWencke

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Ubiquitin-Activating EnzymesMajor topic
MutationMajor topic
Humans
Neoplasms
Animals
Hematologic Neoplasms
Male

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References105

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139,081,801Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome.Hemasphere2024https://conductscience.org/library/papers/39081801PubMed
234,427,584Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1.Blood Adv2021https://conductscience.org/library/papers/34427584PubMed
332,430,504Genetics of progression from MDS to secondary leukemia.Blood2020https://conductscience.org/library/papers/32430504PubMed
426,432,019UBA1: At the Crossroads of Ubiquitin Homeostasis and Neurodegeneration.Trends Mol Med2015https://conductscience.org/library/papers/26432019PubMed
527,346,803The unfolded protein response in immunity and inflammation.Nat Rev Immunol2016https://conductscience.org/library/papers/27346803PubMed
629,334,375A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.Nat Med2018https://conductscience.org/library/papers/29334375PubMed
728,117,417Proteasome inhibitors in cancer therapy.Nat Rev Clin Oncol2017https://conductscience.org/library/papers/28117417PubMed
822,456,334Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage.Cell Cycle2012https://conductscience.org/library/papers/22456334PubMed
932,296,023The role of ubiquitination in tumorigenesis and targeted drug discovery.Signal Transduct Target Ther2020https://conductscience.org/library/papers/32296023PubMed
1037,471,107VEXAS: walking on the edge of malignancy.Blood2023https://conductscience.org/library/papers/37471107PubMed

1 to 10 of 105

See all 105 references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
42,840,941UBA1 as a proteostasis-innate immunity checkpoint: lessons from vexas syndrome and therapeutic implications.Front Immunol2026https://conductscience.org/library/papers/42840941PubMed
42,516,444VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome in a Patient Presenting With Auricular Chondritis.Cureus2026https://conductscience.org/library/papers/42516444PubMed
42,353,870VEXAS Syndrome Beyond UBA1: Genetic Architecture and the Role of Co-Occurring Somatic Mutations-A Focused Review.Genes (Basel)2026https://conductscience.org/library/papers/42353870PubMed
42,284,697Myelodysplasia in VEXAS syndrome.Blood Adv2026https://conductscience.org/library/papers/42284697PubMed
42,200,825VEXAS Syndrome: Clinical Features, Hematologic Involvement, and Clinical Outcomes of Current and Emerging Therapies.Hematol Rep2026https://conductscience.org/library/papers/42200825PubMed
42,137,243X chromosome inactivation, X-linked disorders, and cancer.Front Genet2026https://conductscience.org/library/papers/42137243PubMed
42,136,818The First Reported Case of VEXAS Syndrome in Lebanon: Efficacy of Azacitidine as a Therapeutic Option-Case Report.Case Rep Hematol2026https://conductscience.org/library/papers/42136818PubMed
41,681,985Genome Instability and Somatic Mutagenesis in Autoimmune Diseases.Cancers (Basel)2026https://conductscience.org/library/papers/41681985PubMed
41,551,624Rapid cutaneous remission response to tofacitinib and systemic corticosteroids in VEXAS syndrome with a novel UBA1 mutation.JAAD Case Rep2026https://conductscience.org/library/papers/41551624PubMed
41,339,070
Association for Clinical Genomic Science (ACGS) guidelines for the classification of oncogenicity of somatic variants in cancer: recommendations by the UK somatic variant interpretation group (SVIG-UK).
J Med Genet2026https://conductscience.org/library/papers/41339070PubMed

1 to 10 of 14

See all 14 cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EIF2AK39,451PubTator's text mininghttps://conductscience.org/library/genes/9451NCBI Gene
UBA17,317PubTator's text mininghttps://conductscience.org/library/genes/7317NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39347709

GET https://conductscience.org/api/papers/v1/39347709/references?page=2

API referenceFor AI assistants